DE69434491D1 - Hautpflaster enthaltend testosteron und gegebenenfalls estrogen - Google Patents

Hautpflaster enthaltend testosteron und gegebenenfalls estrogen

Info

Publication number
DE69434491D1
DE69434491D1 DE69434491T DE69434491T DE69434491D1 DE 69434491 D1 DE69434491 D1 DE 69434491D1 DE 69434491 T DE69434491 T DE 69434491T DE 69434491 T DE69434491 T DE 69434491T DE 69434491 D1 DE69434491 D1 DE 69434491D1
Authority
DE
Germany
Prior art keywords
estrogen
testosterone
patient contains
skin patient
contains testosterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434491T
Other languages
English (en)
Other versions
DE122007000006I1 (de
DE69434491T2 (de
DE69434491T3 (de
Inventor
Charles D Ebert
Dinesh C Patel
Norman Alan Mazer
Srinivasan Venkateshwaran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actavis Laboratories UT Inc
Original Assignee
Actavis Laboratories UT Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22277259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69434491(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actavis Laboratories UT Inc filed Critical Actavis Laboratories UT Inc
Publication of DE69434491D1 publication Critical patent/DE69434491D1/de
Publication of DE69434491T2 publication Critical patent/DE69434491T2/de
Application granted granted Critical
Publication of DE69434491T3 publication Critical patent/DE69434491T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69434491T 1993-08-03 1994-07-27 Hautpflaster enthaltend testosteron und gegebenenfalls östrogen Expired - Lifetime DE69434491T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99923 1993-08-03
US08099923 US5460820B1 (en) 1993-08-03 1993-08-03 Method for providing testosterone and optionally estrogen replacement therapy to women
PCT/US1994/008637 WO1995003764A1 (en) 1993-08-03 1994-07-27 Skin patches and methods for providing testosterone

Publications (3)

Publication Number Publication Date
DE69434491D1 true DE69434491D1 (de) 2006-02-02
DE69434491T2 DE69434491T2 (de) 2006-06-22
DE69434491T3 DE69434491T3 (de) 2009-04-30

Family

ID=22277259

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69434491T Expired - Lifetime DE69434491T3 (de) 1993-08-03 1994-07-27 Hautpflaster enthaltend testosteron und gegebenenfalls östrogen
DE1994634491 Pending DE122007000006I1 (de) 1993-08-03 1994-07-27 Hautpflaster enthaltend Testosteron und gegebenenfalls Estrogen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1994634491 Pending DE122007000006I1 (de) 1993-08-03 1994-07-27 Hautpflaster enthaltend Testosteron und gegebenenfalls Estrogen

Country Status (17)

Country Link
US (1) US5460820B1 (de)
EP (2) EP0712303B2 (de)
JP (4) JPH09500653A (de)
KR (1) KR0180030B1 (de)
CN (2) CN1550233A (de)
AT (1) ATE304845T1 (de)
AU (1) AU690578B2 (de)
CA (1) CA2168879C (de)
DE (2) DE69434491T3 (de)
DK (1) DK0712303T4 (de)
ES (1) ES2245777T5 (de)
LU (1) LU91309I2 (de)
NL (1) NL300259I2 (de)
NO (1) NO316844B1 (de)
TW (1) TW492881B (de)
WO (1) WO1995003764A1 (de)
ZA (1) ZA945782B (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
DE19517145C2 (de) * 1995-05-10 2000-02-24 Hexal Pharmaforschung Gmbh Transdermales therapeutisches System (TTS) zur Verabreichung von Testosteron
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
AU2746397A (en) * 1996-04-30 1997-11-19 Theratech, Inc. Transdermal administration of steroid hormones using diethanolamides of c12-c18 fatty acids as permeation enhancers
US6228852B1 (en) * 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
US5783208A (en) * 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
DE19646050A1 (de) * 1996-11-08 1998-05-14 Labtec Gmbh Transdermales System mit einem speziellen Süßstoff zur Erhöhung der transdermalen Bioverfügbarkeit
US5951999A (en) 1997-02-21 1999-09-14 Adhesives Research, Inc. Transdermal pressure sensitive adhesive drug delivery system
US6056972A (en) * 1997-02-26 2000-05-02 Dimera, Llc Method for reducing coronary artery reactivity
CA2281876A1 (en) * 1997-02-28 1998-09-03 Minnesota Mining And Manufacturing Company Transdermal device for the delivery of testosterone
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
GB9720470D0 (en) * 1997-09-25 1997-11-26 Ethical Pharmaceuticals South Inhibition of crystallization in transdermal devices
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
US6692763B1 (en) * 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
CA2309633C (en) * 1998-10-23 2010-12-14 Idea Innovative Dermale Applikationen Gmbh Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates
EP1031347B1 (de) 1999-01-27 2002-04-17 Idea Ag Transnasaler Transport bzw. Impfung mit hochadaptierbaren Trägern
DE69901377T2 (de) 1999-01-27 2003-01-02 Idea Ag Nichtinvasive Impfung durch die Haut
PE20010404A1 (es) * 1999-06-11 2001-04-09 Watson Pharmaceuticals Inc Combinacion de esteroides androgenicos no orales y compuestos estrogenicos y su uso en mujeres
AU2004222794B2 (en) * 1999-06-11 2007-03-08 Watson Pharmaceuticals, Inc. Non-oral androgenic steroids for women
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
CN1240384C (zh) * 1999-11-04 2006-02-08 美国爱科赛尔制药有限公司 石杉碱经皮给药制剂
US20050042271A1 (en) * 1999-11-19 2005-02-24 Xel Herbaceuticals, Inc . Transdermal delivery system for alkaloids of aconitum species
US6896898B1 (en) 1999-11-19 2005-05-24 Xel Herbaceuticals, Inc. Transdermal delivery system for alkaloids of aconitum species
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US6582724B2 (en) 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6562369B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6586000B2 (en) 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
KR100403051B1 (ko) * 2000-07-25 2003-10-23 일양약품주식회사 음낭 외 피부에 적용가능한 남성호르몬 경피흡수 패취제
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
US7921999B1 (en) 2001-12-20 2011-04-12 Watson Laboratories, Inc. Peelable pouch for transdermal patch and method for packaging
US20030191096A1 (en) * 2002-04-03 2003-10-09 Leonard Thomas W. Method of hormonal therapy
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
CA2433101A1 (en) * 2003-06-23 2004-12-23 Igor Gonda Method of treatment of a female suffering from androgen insufficiency
GB0409498D0 (en) * 2004-04-28 2004-06-02 Hunter Fleming Ltd Transdermal steroid formulation
US20070196453A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US8741333B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
US8741332B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
CA2584475A1 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US10137135B2 (en) 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
PL2450041T3 (pl) 2005-10-12 2019-02-28 Unimed Pharmaceuticals, Llc Ulepszony żel zawierający testosteron do zastosowania do leczenia hipogonadyzmu
US20080015170A1 (en) * 2005-12-01 2008-01-17 The Procter & Gamble Company Method of treating menopausal women transdermally with testosterone
EP1839705A1 (de) 2006-03-27 2007-10-03 Universidad de Alcala Transkutanes Lasertherapiepflaster
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
US7820623B2 (en) 2006-10-25 2010-10-26 Amgen Inc. Conjugated toxin peptide therapeutic agents
CA2687141C (en) 2007-05-22 2014-04-01 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US20090285893A1 (en) * 2008-05-19 2009-11-19 The Procter & Gamble Company Treatment of heart failure in women
US20100022991A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and device for maintaining physiological levels of steroid hormone in a subject
US20100061976A1 (en) * 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
US20100022494A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100022497A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
EP2506838A1 (de) * 2009-12-01 2012-10-10 Noven Pharmaceuticals, INC. Transdermale testosteronvorrichtung und freisetzung
CN103930437A (zh) 2011-03-16 2014-07-16 安姆根有限公司 Nav1.3和Nav1.7的强效及选择性抑制剂
CN102772417B (zh) * 2012-07-24 2014-01-29 上海现代药物制剂工程研究中心有限公司 包载睾酮的自黏性弹性体基质的周效经皮贴剂及制法
JP6114841B2 (ja) 2013-02-28 2017-04-12 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． グリコピロレート塩
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
EP2970408B1 (de) 2013-03-12 2018-01-10 Amgen Inc. Hochwirksame und selektive inhibitoren von nav1.7
US9452174B2 (en) * 2014-08-20 2016-09-27 Professional Compounding Centers Of America Oral transmucosal pharmaceutical compositions including testosterone and a C-SERM
PT109445B (pt) 2016-06-08 2018-11-06 Hovione Farm Sa Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
AU2019299538A1 (en) * 2018-07-05 2021-01-28 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
AU644815B2 (en) † 1989-09-08 1993-12-23 Ortho-Mcneil Pharmaceutical, Inc. Solid matrix system for transdermal drug delivery
US5122383A (en) * 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5211952A (en) 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
DE4210165A1 (de) † 1991-07-30 1993-02-04 Schering Ag Transdermale therapeutische systeme

Also Published As

Publication number Publication date
DE122007000006I1 (de) 2007-04-19
NL300259I2 (nl) 2007-09-03
CN1131907A (zh) 1996-09-25
AU7517894A (en) 1995-02-28
US5460820B1 (en) 1999-08-03
WO1995003764A1 (en) 1995-02-09
US5460820A (en) 1995-10-24
ZA945782B (en) 1995-03-10
CN1142753C (zh) 2004-03-24
JP2002121136A (ja) 2002-04-23
JP2009185074A (ja) 2009-08-20
JPH09500653A (ja) 1997-01-21
CA2168879A1 (en) 1995-02-09
EP1604651A1 (de) 2005-12-14
DK0712303T3 (da) 2006-01-16
JP2005263814A (ja) 2005-09-29
NO960445D0 (no) 1996-02-02
CA2168879C (en) 2007-03-27
ATE304845T1 (de) 2005-10-15
EP0712303A4 (de) 1997-04-23
DE69434491T2 (de) 2006-06-22
EP0712303A1 (de) 1996-05-22
EP0712303B1 (de) 2005-09-21
ES2245777T5 (es) 2009-03-01
DK0712303T4 (da) 2009-01-26
NO960445L (no) 1996-03-26
DE69434491T3 (de) 2009-04-30
LU91309I2 (fr) 2007-06-15
CN1550233A (zh) 2004-12-01
KR0180030B1 (ko) 1999-04-01
NL300259I1 (nl) 2007-04-02
KR960703545A (ko) 1996-08-31
AU690578B2 (en) 1998-04-30
ES2245777T3 (es) 2006-01-16
EP0712303B2 (de) 2008-09-17
NO316844B1 (no) 2004-06-01
TW492881B (en) 2002-07-01

Similar Documents

Publication Publication Date Title
DE69434491D1 (de) Hautpflaster enthaltend testosteron und gegebenenfalls estrogen
FI953926A (fi) Hormonin palautushoito
FI956014A (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
DE19680582D2 (de) Hormonpflaster
ID28003A (id) Turunan-turunan adamantana
PL323798A1 (en) Application of derivatives of vitamin d4 in treating skin diseases
MX9801596A (es) Composiciones aliviadoras del prurito, cosmeticas y farmaceuticas o ambas.
DE69824164D1 (de) Arzneizubereitungen zur behandlung sexueller funktionsstörungen
DE59608150D1 (de) Transdermales therapeutisches system (tts) zur verabreichung von testosteron
NZ503372A (en) Chemical supplementation of bone by exposing bone to a therapeutic compound and applying a potential difference across the bone or tissue
IL131478A0 (en) Methods for treatment of scar tissue
WO1996001100A3 (de) Hydrogel für die applikation von therapeutischen und/oder kosmetischen wirkstoffen an die haut
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
UA7951A (uk) Спосіб сочетаної вакуум-лазерної терапії
AU5870298A (en) 1,4-dihydropyridin derivatives and their use in therapy
UA22223A (uk) Спосіб лікуваhhя захворюваhь оргаhа зору
MX9604426A (es) Reduccion de irritacion de la piel durante el surtido por electrotransporte.
PL332035A1 (en) Transdermal therapeutic system including an estriol-containing composition of active substances
UA30329A (uk) Спосіб лікування хронічних запальних захворювань придатків матки
DK0678027T3 (da) Antiatherosclerotiske midler
MX9706825A (es) El uso farmacologico de ciertos derivados de cistina.
UA8280A (uk) Спосіб лікування псоріазу
UA10259A (uk) Протинабряковий лікарський препарат "нейрополіосм"
UA32241A (uk) Спосіб лікування запалювальних процесів у експериментальних тварин
GB9517072D0 (en) Dienes for use in the treatment of skin diseases and cancer

Legal Events

Date Code Title Description
8363 Opposition against the patent
V448 Application of spc

Free format text: PRODUCT NAME: TESTOSTERON, DAS IN EINER TAEGLICHEN DOSIS VON 50 BIS 500 MIKROGRAMM FREIGESETZTWIRD; REGISTRATION NO/DATE: EU/1/06/352/001 - EU/1/06/352/003; 20060728

Spc suppl protection certif: 12 2007 000 006

Filing date: 20070126

8366 Restricted maintained after opposition proceedings